11920466

Source:http://linkedlifedata.com/resource/pubmed/id/11920466

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0242957, umls-concept:C0599894, umls-concept:C0600139, umls-concept:C2003903
pubmed:issue	4
pubmed:dateCreated	2002-3-28
pubmed:abstractText	The clinical effects of targeting HER-2 in prostate carcinoma are not known. This study explored the feasibility of molecular profiling to determine the correlation between HER-2 expression, hormonal sensitivity, and the antitumor effects of trastuzumab and paclitaxel in patients with prostate carcinoma.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/CA 09207
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0374236
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic, http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel, http://linkedlifedata.com/resource/pubmed/chemical/Prostate-Specific Antigen, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2, http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	0008-543X
pubmed:author	pubmed-author:KellyW KevinWK, pubmed-author:KennesonKateK, pubmed-author:MorrisMichael JMJ, pubmed-author:OsmanImanI, pubmed-author:ReuterVictor EVE, pubmed-author:ScherHoward IHI, pubmed-author:SlovinSusan FSF, pubmed-author:VerbelDavidD
pubmed:copyrightInfo	Copyright 2002 American Cancer Society. DOI 10.1002/cncr.10339
pubmed:issnType	Print
pubmed:day	15
pubmed:volume	94
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	980-6
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:11920466-Aged, pubmed-meshheading:11920466-Aged, 80 and over, pubmed-meshheading:11920466-Antibodies, Monoclonal, pubmed-meshheading:11920466-Antibodies, Monoclonal, Humanized, pubmed-meshheading:11920466-Antineoplastic Agents, pubmed-meshheading:11920466-Antineoplastic Agents, Phytogenic, pubmed-meshheading:11920466-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:11920466-Carcinoma, pubmed-meshheading:11920466-Disease Progression, pubmed-meshheading:11920466-Gene Expression Regulation, Neoplastic, pubmed-meshheading:11920466-Humans, pubmed-meshheading:11920466-Infusions, Intravenous, pubmed-meshheading:11920466-Male, pubmed-meshheading:11920466-Middle Aged, pubmed-meshheading:11920466-Paclitaxel, pubmed-meshheading:11920466-Prostate-Specific Antigen, pubmed-meshheading:11920466-Prostatic Neoplasms, pubmed-meshheading:11920466-Receptor, erbB-2, pubmed-meshheading:11920466-Treatment Outcome
pubmed:year	2002
pubmed:articleTitle	HER-2 profiling and targeting in prostate carcinoma.
pubmed:affiliation	Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Clinical Trial, Phase II